Clinical Trials Logo

Safety clinical trials

View clinical trials related to Safety.

Filter by:

NCT ID: NCT01818869 Completed - Healthy Subjects Clinical Trials

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects

Start date: January 2014
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8848 in healthy subjects.

NCT ID: NCT01815684 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the safety (including the effect on cardiac intervals), tolerability, the effects on the Central Nervous System (CNS), as well as the CNS side effect profile of single ascending doses of ASP3652 in healthy, Caucasian male and female subjects.

NCT ID: NCT01789528 Completed - Pharmacokinetics Clinical Trials

A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers

Start date: August 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the effect of administration of CAZ-AVI and CXL on the intestinal flora of male and female healthy volunteers after multiple administrations over 7 days. An assessment of the effect on intestinal flora is an important aspect to understand for the safe clinical use of the investigational products and is expected by regulatory agencies.

NCT ID: NCT01697007 Completed - HIV Clinical Trials

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique

TaMoVac II
Start date: November 2012
Phase: Phase 2
Study type: Interventional

Electroporation will increase the efficiency of DNA priming in terms of immune responses and will lead to a dose sparing DNA vaccine regimen. Furthermore increased DNA vaccine concentration will reduce the number of shots necessary to deliver the full dose and induce comparable immune responses as with lower DNA vaccine concentrations.

NCT ID: NCT01647854 Completed - Safety Clinical Trials

Operation of a Mobile Telemedicine System in the EMS

Start date: August 2012
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the safety and efficacy of the operation of a prehospital teleconsultation system in the Emergency Medical Service.

NCT ID: NCT01636024 Completed - Pharmacokinetics Clinical Trials

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Start date: September 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and biomarkers in blood when the drug is administered inhaled to healthy subjects

NCT ID: NCT01576666 Completed - Gastric Cancer Clinical Trials

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Start date: July 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and recurrent glioblastoma multiforme).

NCT ID: NCT01568567 Completed - Safety Clinical Trials

Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults

BSSII
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Lactobacilli are commensal bacteria common to the gut of all mammals studied and traditionally associated with foods are considered safe.The established safe use on a diversity of foods and supplement products worldwide supports this conclusion. Lactobacillus reuteri is one species of Lactobacillus that naturally inhabits the gastrointestinal tract of humans and is one of the few autochthonous (indigenous) Lactobacillus species in infants as well as adults. Although the tolerability of DSM 17938 in a tablet formulation has earlier been established, it is desirable to repeat the assessment in this novel formulation.

NCT ID: NCT01568281 Completed - Pharmacokinetics Clinical Trials

Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects

Start date: April 2012
Phase: Phase 1
Study type: Interventional

This study is to investigate whether anastrozole ODF is bioequivalent with Arimidex tablet after a single oral administration of each anastrozole formulation.

NCT ID: NCT01560884 Completed - Safety Clinical Trials

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

SPI-014
Start date: April 2012
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to study safety, tolerability, and phosphate binding capacity of Renazorb (SPI-014) in healthy volunteers before conducting trials in patients with renal failure. Renal excretion of phosphate is expected to decrease and fecal excretion of phosphate is expected to increase after treatment.